Exogems secures CHF 500K in seed-stage financing from business angels
Share this article
Exogems secures CHF 500’000 in seed-stage financing from business angels to advance therapeutic exosome development.
Exogems SA, a pioneering Swiss biotech company developing innovative therapeutic exosomes derived from microfragmented adipose tissue, today announced the successful completion of a CHF 500’000 fundraising round from business angels. This significant investment will fuel the company’s mission to harness the potential of exosomes in treating inflammation, infection, and cancer.
Exogems’ pioneering approach leverages the unique properties of exosomes, which are tiny vesicles released by cells that can carry therapeutic molecules to specific targets within the body. By utilising microfragmented adipose tissue as a source of exosomes, the company aims to create a new generation of treatments that are more eOective, safer, and more targeted than traditional therapies.
“We are thrilled to have secured this funding from a group of experienced business angels, who share our vision for the transformative potential of therapeutic exosomes,” said Dr. Bisognano Carmelo, CEO of Exogems. “This investment will enable us to accelerate our research and development eOorts, bringing us closer to clinical trials and ultimately, to patients in need of innovative treatments.”
The seed-stage financing will support Exogems’ ongoing research and development activities, including the optimisation of its exosome production and purification processes, as well as the initiation of preclinical studies to evaluate the safety and eOicacy of its therapeutic exosomes.
“Exogems’ innovative approach to harnessing the power of exosomes has the potential to revolutionise the treatment of various diseases,” said Prof Carlo Tremolada, Chairman of Exogems. “We are excited to pursue our journey towards bringing these groundbreaking therapies to patients worldwide.”
Exogems’ successful fundraising round marks an important milestone in the company’s growth trajectory, demonstrating the interest and enthusiasm of the investment community in its pioneering technology.
Source: press release